RBC Capital raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $420 from $408 and keeps a Sector Perform rating on the shares. Alyftrek third-party scripts since launch appear on the surface to reflect limited uptake, but meaningful concurrent declines in Trikafta scripts leave open a good possibility that initial conversion to Alyftrek may be faster than expected and that Alyftrek uptake may just not yet be adequately captured, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Marks’ Resignation Is a ‘Blow for Biotech Industry,’ Says RBC Analyst as Biotech Stocks Fall
- Biotech stocks slide as Marks resignation seen being negative for sector
- Marks resignation ‘not good’ for biotech sector, says RBC
- Vertex Pharmaceuticals: Promising Growth Amid Setbacks with Strong Pipeline and Transformative Diabetes Program
- Vertex Pharmaceuticals price target raised to $567 from $555 at BofA